BeOne

Fierce Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

HARMONi-6 marks the first phase 3 trial in which a regimen has beaten the combination of a PD-1 inhibitor and chemotherapy on PFS in first-line NSCLC.

Angus Liu Oct 19, 2025 10:45am

An arrow incrementally going up stairs before pointing straight up Blue background

BeOne asset hits primary endpoint, tees up blood cancer filings

Aug 29, 2025 9:50am

Pfizer’s reputation wrangler plans departure—Chutes & Ladders

Jul 11, 2025 8:30am

Novartis inks $175M option deal for Sironax’s BBB tech

Jul 9, 2025 10:29am

BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects

Apr 3, 2025 8:05am

graphic image of different colored hands shaking

BeiGene, Brii and Ideaya ring in 2025 with deals

Jan 2, 2025 8:30am